Alzheimer's drug approvals create prescribing dilemmas

Science. 2024 Nov;386(6721):472-473. doi: 10.1126/science.adu2383. Epub 2024 Oct 31.

Abstract

Clinicians and patients weigh modest benefits of the antibodies against sometimes-serious side effects.

Publication types

  • News

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Drug Approval*
  • Humans
  • Vereinigte Staaten
  • United States Food and Drug Administration*

Substances

  • Antibodies, Monoclonal, Humanized
  • aducanumab